SKF83959, an agonist of phosphatidylinositol-linked dopamine receptors, prevents renewal of extinguished conditioned fear and facilitates extinction

Fu-Feng Chen,Can-Ming Wang,Hong-Sheng Chen,Ji Wang,Qian-Qian Han,Yu Cao,Tian-Tian Shen,Yuan-Jian Yang,Zhuang-Li Hu,Fang Wang,Jian-Guo Chen,Peng-Fei Wu
DOI: https://doi.org/10.1016/j.brainres.2020.147136
IF: 3.61
2020-12-01
Brain Research
Abstract:<p>Fear-related anxiety disorders, such as social phobia and post-traumatic stress disorder, are partly explained by an uncontrollable state of fear. An emerging literature suggests dopamine receptor-1 (D<sub>1</sub> receptor) in the amygdala is involved in the regulation of fear memory. An early study has reported that amygdaloid D<sub>1</sub> receptor (D<sub>1</sub>R) is not coupled to the classic cAMP-dependent signal transduction. Here, we investigated whether SKF83959, a typical D<sub>1</sub>R agonist that mainly activates a D<sub>1</sub>-like receptor-dependent phosphatidylinositol (PI) signal pathway, facilitates fear extinction and reduces the return of extinguished fear. Interestingly, long-term loss of fearful memories can be induced through a combination of SKF83959 (1 mg/kg/day, i.p., once daily for one week) pharmacotherapy and extinction training. Furthermore, sub-chronic administration of SKF83959 after fear conditioning reduced fear renewal and reinstatement in the mice. We found that the activation D<sub>1</sub>R and PI signaling in the amygdala was responsible for the effect of SKF83959 on fear extinction. Additionally, SKF83959 significantly promoted the elevation of brain-derived neurotrophic factor (BDNF) expression, possibly by the cAMP response element binding protein (CREB) -directed gene transcription. Given the beneficial effects on extinction, SKF83959 may emerge as a candidate pharmacological approach for improving cognitive-behavioral therapy on fear-related anxiety disorders.</p>
neurosciences
What problem does this paper attempt to address?